Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q1 2024 call → NOWe need to determine if management describes that successive engagements of the same kind are coming in at progressively larger size. The question asks about whether the company's deals, orders, contracts, projects, customers, sites, or programs are individually bigger, broader, or longer than before. Looking at the transcript, management discusses new sales, retention, and growth. They mention strong sales momentum, 50% year-over-year growth in ACV (annual contract value). But does that indicate that the size of each deal is larger? They talk about "new sales" and "ACV" growth, but that could be due to more deals, not necessarily larger deals. They also mention "tenured reps" and "productivity improvement" which suggests more sales per rep, but not necessarily larger individual deals. They mention "customer size slightly larger, but not significant" in response to a question about quality of new sales. That suggests that the average customer size is slightly larger, but not a major shift. The question asks about "progressively larger size" - meaning each new engagement is bigger than the last. The transcript does not convey that the company is landing larger deals over time. They talk about strong sales, but not about the average deal size escalating. They also mention "we nearly achieved positive sequential core worksite employee growth" and "offsetting attrition with new sales" - that's about volume, not size. There is no mention of deals being larger, broader, or longer. No comparison against the company's own past in terms of deal size. The only mention of size is "customer size slightly larger" which is not a strong statement of escalation. Also, they don't mention that larger deals are already real and recurring, or that they are early in this trend. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.